The FDA initially granted a Priority Review, then the agency extended the review period, with a decision now anticipated in 4Q 2025
Future studies should aim to clarify the relationship between GLP-1 agonist use and aspiration risk, including factors such as duration of use, type of GLP-1 agonist (short- vs
Overall, investing in this years theme of GLP-1s disruption of various sectors of the economy has been profitable
Giulivi C, Kato K, Cooper CE (2006) Nitric oxide regulation of mitochondrial oxygen consumption I: cellular physiology
The pancreas has both an exocrine and endocrine role
Andrology 5(2):256261 Tam SW, Worcel M, Wyllie M (2001) Yohimbine: a clinical review